In Bloomberg BusinessWeek, Michael Beauvais Comments on Optimism Fueling Life Sciences Industry Dealmaking

In The News
January 11, 2024

In a Bloomberg BusinessWeek article republished in Yahoo Finance, life sciences partner Michael Beauvais commented on the optimistic outlook for life sciences dealmaking surrounding the JP Morgan Healthcare Conference.

Among the sectors within life sciences and broader healthcare industry that are attracting M&A interest include targeted cancer treatments, weight-loss and diabetes drugs, neuroscience therapies, and gene-editing technologies such as CRISPR.

The Nasdaq Biotechnology Index is the highest it’s been since early 2022 and looks for a return to prepandemic deal levels.